Evaluation of Safety and Systemic Pharmacokinetics After Single and Repeat Doses of Abicipar Pegol (AGN-150998) Intravitreal Injections in Patients With Neovascular Age-Related Macular Degeneration
Phase of Trial: Phase I
Latest Information Update: 09 Feb 2018
At a glance
- Drugs Abicipar pegol (Primary)
- Indications Wet age-related macular degeneration
- Focus Pharmacokinetics
- Sponsors Allergan
- 06 Feb 2018 Status changed from active, no longer recruiting to completed.
- 27 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 08 Dec 2016 Status changed from not yet recruiting to recruiting.